In this recent presentation given by our Product Manager, Stephen Maughan, Dphil, he will explore three ways mass photometry enhances antibody development workflows:

1. Early Risk Mitigation: Conduct aggregation measurements earlier in the development process using nanograms of sample when material is limited.
2. Accelerated Analytics: Obtain rapid, high-resolution aggregation data within minutes.
3. Streamlined Project Timelines: Eliminate the need for extensive method development and sample preparation across different antibody formats, including monoclonal antibodies (mAbs), bispecific antibodies (BsAbs), and ADCs.

Through real-world case studies, we will demonstrate the orthogonal value of mass photometry to SEC. Join us to discover how integrating mass photometry into antibody development workflows can drive faster, more reliable decision-making.